biostudies-literatureUnknown6(1)Loughman J<h4>Purpose</h4>To investigate the safety, tolerability, and signals of effect of MyopiaX, a smartphone app that selectively delivers blue light to the optic nerve head to control myopia progression in children and adolescents.<h4>Design</h4>Multicenter, randomized, active-controlled, examiner-masked proof-of-concept clinical trial (ClinicalTrials.gov identifier NCT04967287).<h4>Participants</h4>Eligible children aged 6 to 12 years, with myopia of cycloplegic spherical equivalent refraction (SER) between -0.75 and -5.00 diopters (D) at baseline. Children were screened and enrolled between November 2021 and September 2023.<h4>Methods</h4>Children were randomly assigned in a 2:1 ratio to MyopiaX or active control. Participants were instructed to use MyopiaX for 10 minutes twice daily for theOphthalmology science100973https://www.ebi.ac.uk/biostudies/studies/S-EPMC12719902biostudies-literatureMyopiaX-1 Safety and Efficacy of a Novel Approach to Slow Juvenile Myopia Progression: A Multicenter, Randomized, Controlled Trial.PMC12719902Kaymak HMorales Ballus MBatres LGosheva MFernandes PRMattern AISilva-Leite SKlaver CPolling JRPorras Angel PDeuter CPastrana Robles CPeters TDahlmann-Noor AHMyopiaX-1 Study GroupFlitcroft IBodas Romero JLingham GAmorim-de-Sousa APeixoto-de-Matos SCCarpena Torres CMuller PLSerramito Blanco MGanan EJGonzalez-Meijome JMDevenijn MKatona TCarracedo GFolga RBeck ALorenz KArroyo Del Arroyo CLoughman JNeller BLiman KfalseMyopiaX-1 Safety and Efficacy of a Novel Approach to Slow Juvenile Myopia Progression: A Multicenter, Randomized, Controlled Trial.<h4>Purpose</h4>To investigate the safety, tolerability, and signals of effect of MyopiaX, a smartphone app that selectively delivers blue light to the optic nerve head to control myopia progression in children and adolescents.<h4>Design</h4>Multicenter, randomized, active-controlled, examiner-masked proof-of-concept clinical trial (ClinicalTrials.gov identifier NCT04967287).<h4>Participants</h4>Eligible children aged 6 to 12 years, with myopia of cycloplegic spherical equivalent refraction (SER) between -0.75 and -5.00 diopters (D) at baseline. Children were screened and enrolled between November 2021 and September 2023.<h4>Methods</h4>Children were randomly assigned in a 2:1 ratio to MyopiaX or active control. Participants were instructed to use MyopiaX for 10 minutes twice daily for the2026-01-01T00:00:00Z2026 Jan2026-06-08T05:26:54.952Z2026-06-08T03:08:36.572ZS-EPMC127199024143881810.1016/j.xops.2025.100973